Cancer Research UK launches trial of new lymphoma treatment

January 29, 2014

Cancer Research UK's Drug Development Office (DDO) has launched a new clinical trial to treat lymphoma patients using the body's own immune system to attack cancerous B-cells growing out of control.

B-cells are specialised that work as the factories of the , pumping out antibodies into the blood stream. These antibodies then act as seeker missiles, homing in on targets recognised as harmful to the body and directing immune cells to attack them.

But in B-cell lymphomas, the B-cells themselves are the problem as far more are produced than the body needs. This new therapy uses the body's own weapons against the tumour. In this trial an antibody, called DI-B4, has been designed to target a molecular marker, which is specific to B-cells and young cells destined to become B-cells. By binding to this marker, the antibody signals other immune cells to attack and destroy these B-cells.

B-cell lymphomas account for more than nine in 10 of all Non-Hodgkin lymphomas (NHL) with an estimated 10,500 cases every year in the UK.

This is an early phase trial to test how 40 will deal with the drug which will be led from Southampton General Hospital, with other centres including The Christie hospital in Manchester, the Royal Liverpool University Hospital and the Oxford University Hospital. The study will last four and a half years with an 18 month follow up.

These centres are part of Cancer Research UK's network of Experimental Cancer Medicine Centres (ECMCs) which bring together cancer doctors and scientists to speed up the flow of ideas from the lab bench to a patient's bedside.

Dr Andy Davies, Cancer Research UK medical oncologist and lead researcher for the study from the University of Southampton, said: "Adapting the immune system to fight cancer has become a powerful weapon. Drugs like rituximab, which targets a different B-cell marker, have helped many patients, but far too many relapse or become resistant. DI-B4, which targets a marker of both B-cells and the cells that will grow up to be B-cells, could be a more effective treatment and an important alternative for these patients."

Dr John Radford, Professor of Medical Oncology at the University of Manchester's Institute for Cancer Sciences and trial lead at The Christie NHS Foundation Trust – part of the Manchester Cancer Research Centre, said: "New treatments have made a real impact for patients with lymphoma, but we need more therapies for those with tumours that become resistant. This trial of a new antibody treatment for B-cell lymphoma offers new hope for patients who have otherwise run out of options. It's for exactly this type of innovative research involving specialist doctors, scientists and our patients, all aimed at revolutionising cancer treatment that the Manchester Cancer Research Centre exists."

Dr Nigel Blackburn, director of at Cancer Research UK's Drug Development Office, said: "This trial is a perfect example of how we are beginning to harness the body's immune system to save lives.

"Our scientists are at the cutting edge of the field to find new and powerful ways to treat and using the immune system to do so is something we are heavily investing in as a promising way to treat a broad range of cancers."

Explore further: Clinical trial examines use of human immune system to fight aggressive lung cancer

Related Stories

Clinical trial examines use of human immune system to fight aggressive lung cancer

December 19, 2013
Researchers at the Cincinnati Cancer Center (CCC) and the UC Cancer Institute are conducting a clinical trial examining a method to stimulate the human immune system to destroy or block the growth of lung cancer cells.

Breaking down cancer's defense mechanisms

December 20, 2013
A possible new method for treating pancreatic cancer which enables the body's immune system to attack and kill cancer cells has been developed by researchers.

Double dose of genes can trigger poor cancer survival

January 23, 2014
(Medical Xpress)—Cancer Research UK scientists have shown that accidental DNA doubling in bowel cancer cells could predict which patients have potentially poor survival and help doctors plan their treatment, according to ...

Some immune cells appear to aid cancer cell growth, study finds

September 5, 2013
The immune system is normally known for protecting the body from illness. But a subset of immune cells appear to be doing more harm than good.

New hope in the fight against childhood cancer

July 11, 2013
Cancer Research UK scientists at the University of Southampton are seeing positive results in a pre-clinical trial that could bring treatments for a particular aggressive form of childhood cancer closer to reality.

Targeted treatment is better than chemotherapy in some lung cancer patients

January 13, 2014
(Medical Xpress)—Patients with lung cancer who also have a specific gene rearrangement do better on a new targeted therapy compared with standard chemotherapy, according a study by University of Manchester scientists.

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.